For Indian pharmaceutical companies, this scenario presents a distinct opportunity. Leveraging their established expertise and leadership in global COVID-19 vaccine distribution, along with robust supply chain efficiencies, Indian firms are strategically positioned to capitalize on this market shift. The departure of Chinese players from the market opens a significant gap, which Indian companies are well-equipped to fill .
Bonus issue alert: This smallcap stock goes ex-bonus for a 3:1 issue this week. Do you own?
Metropolis Healthcare’s shares will trade ex-record date for its 3:1 bonus issue on Friday, meaning only shareholders holding the stock by the record date are